GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Barré for every million doses given.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...